Loading...
OTCM
KMSTF
Market cap32mUSD
Mar 18, Last price  
5.06USD
Name

Kadimastem Ltd

Chart & Performance

D1W1MN
OTCM:KMSTF chart
No data to show
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
45.14%
Rev. gr., 5y
-12.93%
Revenues
0k
0240,000323,0001,028,0001,703,000684,000000000
Net income
-12m
L-46.97%
-10,052-12,614,000-15,191,000-17,064,000-19,973,000-21,428,000-23,968,000-25,086,000-21,710,000-26,275,000-22,718,000-12,048,000
CFO
-11m
L-44.55%
-8,633-13,483,000-9,781,000-11,219,000-13,634,000-19,828,000-20,827,000-21,128,000-21,828,000-21,546,000-19,996,000-11,087,000

Profile

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was incorporated in 2008 and is based in Ness Ziona, Israel.
URL
https://www.kadimastem.com/
IPO date
Jun 09, 2013
Employees
31
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
12,913
17,189
Unusual Expense (Income)
NOPBT
(12,913)
(17,189)
NOPBT Margin
Operating Taxes
200
(167)
Tax Rate
NOPAT
(13,113)
(17,022)
Net income
(12,048)
-46.97%
(22,718)
-13.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,732
5,475
BB yield
-2.28%
-1.37%
Debt
Debt current
5,490
5,570
Long-term debt
2,144
4,524
Deferred revenue
Other long-term liabilities
3,653
68
Net debt
3,479
3,702
Cash flow
Cash from operating activities
(11,087)
(19,996)
CAPEX
(23)
(640)
Cash from investing activities
333
(656)
Cash from financing activities
8,590
3,724
FCF
(10,572)
(18,711)
Balance
Cash
4,155
6,392
Long term investments
Excess cash
4,155
6,392
Stockholders' equity
(243,453)
(204,537)
Invested Capital
249,070
212,062
ROIC
ROCE
EV
Common stock shares outstanding
42,424
34,872
Price
5.93
-48.39%
11.49
-66.45%
Market cap
251,574
-37.21%
400,679
-50.61%
EV
255,053
404,381
EBITDA
(10,625)
(15,249)
EV/EBITDA
Interest
252
Interest/NOPBT